The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?
COVID-19
SARS-CoV-2
vaccination
Journal
Central-European journal of immunology
ISSN: 1426-3912
Titre abrégé: Cent Eur J Immunol
Pays: Poland
ID NLM: 9702239
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
07
2022
accepted:
27
02
2023
medline:
11
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
ppublish
Résumé
The aim of this study was to investigate the persistence of SARS-CoV-2 neutralizing antibodies (NAbs) one year after contracting COVID-19. The study included 38 patients - 34 men and 4 women - suffering from COVID-19 between March 15 and May 26, 2020. The median age in the group was 31 years, ranging from 22 to 67 years. The levels of neutralizing antibodies were measured at three time-points - baseline, 6 months, and 12 months. The primary endpoint was a post-infection positive result for NAbs (> 15 AU/ml; Liaison SARS-CoV-2 S1/S2 IgG quantitative test) 12 months after infection. The median level of NAbs after 12 months was 26.5 AU/ml. At the end of observation (12 months), 21 of the 38 patients had a NAb level of >15 AU/ml (positive). The median antibody half-life was 5.8 months. A high percentage of the patients maintained positive levels of antibodies 6 and 12 months after COVID-19 infection. The dynamics of the antibody level decline suggests the need for booster vaccination at least once a year.
Identifiants
pubmed: 37692027
doi: 10.5114/ceji.2023.126206
pii: 50430
pmc: PMC10485689
doi:
Types de publication
Journal Article
Langues
eng
Pagination
92-96Informations de copyright
Copyright © 2023 Termedia.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Acta Pharmacol Sin. 2022 Jan;43(1):64-75
pubmed: 33742107
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Int J Infect Dis. 2021 Apr;105:209-215
pubmed: 33607305
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
Clin Infect Dis. 2022 Aug 24;75(1):e924-e925
pubmed: 34849639
Vaccines (Basel). 2021 Mar 05;9(3):
pubmed: 33807818
J Travel Med. 2022 Dec 27;29(8):
pubmed: 36179099
Rev Esp Geriatr Gerontol. 2021 Sep-Oct;56(5):259-267
pubmed: 33610380
J Med Virol. 2021 May;93(5):3211-3218
pubmed: 33620098
Br Med J. 1967 Sep 23;3(5568):767-9
pubmed: 6043624
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Nutrients. 2019 Sep 04;11(9):
pubmed: 31487871
Cytokine Growth Factor Rev. 2022 Feb;63:10-22
pubmed: 34580015
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Emerg Infect Dis. 2006 Jan;12(1):15-22
pubmed: 16494711
ACS Nano. 2021 Jul 27;15(7):11180-11191
pubmed: 34159781
J Clin Lab Anal. 2021 Jan;35(1):e23609
pubmed: 33222271
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Chem. 2020 Aug 1;66(8):1102-1104
pubmed: 32521002
Lancet Infect Dis. 2021 Feb;21(2):163-164
pubmed: 33341124
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Emerg Microbes Infect. 2020 Dec;9(1):386-389
pubmed: 32065057
Nat Commun. 2021 Mar 22;12(1):1813
pubmed: 33753738
Respir Res. 2020 Aug 27;21(1):224
pubmed: 32854739
J Med Virol. 2021 Apr;93(4):2227-2233
pubmed: 33135795